This assessment documented a significant decrease in volume transfer coefficient (Ktrans) upon treatment, which suggested that Mipsagargin reduces blood flow in hepatic lesions consistent with the expression of PSMA by tumor endothelial cells within these lesions [82]. Here, FOLH1 is linked to neoplasm.